Regulatory Compliance

Taipei – – September 29, 2026 -- ORing Industrial Networking, a Taiwan-based industrial networking specialist with 20 years of market experience, showcased its next-generation IRoN railway Ethernet switch portfolio at InnoTrans 2026.

ORing unveils IRoN switches for onboard rail networks at InnoTrans 2026

ORing's networking equipment has already been deployed in passenger and freight rail projects across Europe, the United States, and Asia. The company positions the IRoN Series as a response to trains carrying more connected devices and data-intensive services, where critical control communications now share infrastructure with video surveillance and passenger information systems.

Washington D.C. – September 29, 2026 -- Implantica AG launched its FDA-approved RefluxStop device in the U.S. market at the American Foregut Society (AFS) 2026 Annual Meeting, drawing an over-capacity crowd of more than 120 surgeons and gastroenterologists that forced organizers to turn away additional attendees.

FDA approval opens U.S. market for non-encircling GERD device

Following its recent Premarket Approval (PMA) from the U.S. Food and Drug Administration, RefluxStop entered a U.S. GERD treatment market estimated at 78 million patients. Unlike conventional anti-reflux surgeries that wrap around the esophagus, RefluxStop is designed to restore natural anatomy without encircling the food passageway, aiming to reduce side effects such as dysphagia and inability to belch or vomit.

Chengdu, China – September 29, 2026 -- iRegene Therapeutics has secured clinical trial clearances in both China and the United States for NouvSight001, an off-the-shelf cell therapy targeting retinitis pigmentosa (RP), a retinal disease affecting roughly 1.5 million people worldwide.

China's NMPA clears Phase I/III trial while FDA grants Phase I/II clearance with special exemption

China's National Medical Products Administration authorized a Phase I/III trial to assess safety, tolerability and preliminary efficacy of NouvSight001 in RP patients. The U.S. FDA separately cleared a Phase I/II trial for the same indication and granted a special exemption, building on the Orphan Drug Designation the agency awarded the program in 2024.

Los Angeles – – September 29, 2026 -- Congress has passed the Accelerating Access to Critical Therapies (ACT) for ALS Reauthorization Act of 2026 (H.R. 8205), sending the bipartisan bill to the President's desk just two days before the underlying program was set to expire on September 30, 2026.

Senate approval follows House passage, clearing the path for a presidential signature

The legislation cleared the U.S. House of Representatives before the Senate gave final approval, moving the bill to the President for signature. Once enacted, the law will extend core ACT for ALS programs through 2031, continuing federal support for ALS research infrastructure and expanded access to investigational therapies.

Shanghai – September 29, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.

Singapore – – September 29, 2026 -- The Responsible Fintech Institute (RFI) has appointed Professor Lawrence Loh, Associate Professor Eugene K.B. Tan, Professor Louis Chen and Ms Farah Jaafar as Executive Fellows, while elevating Distinguished Professor Patrick H. M. Loh to Co-Founder.

RFI expands leadership bench as digital finance regulation intensifies

The nonprofit, based in Singapore, said the appointments deepen its expertise in law, governance, digital policy and cross-border capital markets as regulators and institutions push to ground digital asset, AI and cross-border payment innovation in legal and ethical frameworks.

Washington – September 29, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.

Truth Initiative warns weakened review could undermine public health protections

Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.

Phoenix – September 29, 2026 -- AZP Insurance Specialists has awarded Platinum certification to Gateless' Smart Underwrite®, marking the first technology provider to clear AZP's new AI Mortgage Technology Certification framework at its highest of four tiers.

Gateless earns top rating after 230,000 loans processed with zero claims

The Platinum designation reflects the performance of more than 230,000 loans manufactured and sold by lenders using Smart Underwrite®, all without a single claim filed. AZP said the certification evaluated the platform's governance, controls, auditability and operational maturity before granting the top rating.

Detroit – September 29, 2026 -- Rocket Mortgage will become the first mortgage lender to adopt VantageScore 4.0 as its preferred credit scoring model for eligible loans, starting in the fourth quarter of 2026.

Rocket Mortgage found VantageScore 4.0 qualifies more clients while cutting scoring costs

Following roughly four months of testing, the lender determined VantageScore 4.0 helped more clients move forward in the mortgage process and reduced credit scoring costs. So far in 2026, Rocket Mortgage pulled 1.4 million credit reports using both VantageScore and FICO models to compare outcomes.

Clients who saved with the new model averaged $1,600 at closing

The lender's internal study found VantageScore 4.0 opens access for some clients who would otherwise go unserved and allows many to secure mortgages on better pricing terms. For those who benefited, average savings totaled $1,600 at closing.

Pune – September 29, 2026 -- The global ethylene oxide market reached USD 62.95 billion in 2025 and is forecast to grow at a 4.59% CAGR through 2034, hitting USD 94.28 billion, according to a new report from Maximize Market Research.

Asia-Pacific dominates production and consumption, led by China, India, Japan and South Korea

The region's scale in petrochemical manufacturing, PET resin output and polyester fiber production has made it the largest ethylene oxide market as of 2025. Continued capital deployment into petrochemical facilities, healthcare infrastructure and industrial manufacturing is expected to sustain the region's lead through the forecast period.